BACKGROUND: High body mass index (BMI) is associated not only with a higher incidence of breast cancers but also with poorer prognosis. It is speculated that both enhanced production of estrogens and other factors associated with obesity are involved in these associations, but the biological characteristics associated with high BMI have yet to be thoroughly identified. METHODS: We studied 525 breast cancers, focusing on biological differences between tumors associated with high and low BMI and by immunohistochemically defined intrinsic subtype. Ki67 expression levels were used to differentiate luminal A from luminal B estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)-breast cancers. RESULTS: Premenopausal patients with high BMI showed a significantly higher frequency of lymph node metastasis (46.4 % vs. 22.9 %, P = 0.005) and tended to have a larger tumor size (P = 0.05) and higher nuclear grade (P = 0.07) than those with low BMI. These differences were not observed among postmenopausal patients. BMI was not associated with distribution of breast cancer subtypes, and ER, progesterone receptor (PR), and Ki67 expression levels of each subtype showed no differences between high and low BMI among premenopausal patients. CONCLUSION: Higher BMI might influence aggressive tumor characteristics among premenopausal patients, but its influence on ER, PR, and Ki67 expression levels seems to be limited.
BACKGROUND: High body mass index (BMI) is associated not only with a higher incidence of breast cancers but also with poorer prognosis. It is speculated that both enhanced production of estrogens and other factors associated with obesity are involved in these associations, but the biological characteristics associated with high BMI have yet to be thoroughly identified. METHODS: We studied 525 breast cancers, focusing on biological differences between tumors associated with high and low BMI and by immunohistochemically defined intrinsic subtype. Ki67 expression levels were used to differentiate luminal A from luminal B estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)-breast cancers. RESULTS: Premenopausal patients with high BMI showed a significantly higher frequency of lymph node metastasis (46.4 % vs. 22.9 %, P = 0.005) and tended to have a larger tumor size (P = 0.05) and higher nuclear grade (P = 0.07) than those with low BMI. These differences were not observed among postmenopausal patients. BMI was not associated with distribution of breast cancer subtypes, and ER, progesterone receptor (PR), and Ki67 expression levels of each subtype showed no differences between high and low BMI among premenopausal patients. CONCLUSION: Higher BMI might influence aggressive tumor characteristics among premenopausal patients, but its influence on ER, PR, and Ki67 expression levels seems to be limited.
Authors: Amanda I Phipps; Kathleen E Malone; Peggy L Porter; Janet R Daling; Christopher I Li Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-07-29 Impact factor: 4.254
Authors: Giuseppe Viale; Meredith M Regan; Eugenio Maiorano; Mauro G Mastropasqua; Rastko Golouh; Tiziana Perin; Robert W Brown; Anikó Kovács; Komala Pillay; Christian Ohlschlegel; Stephen Braye; Piergiovanni Grigolato; Tiziana Rusca; Richard D Gelber; Monica Castiglione-Gertsch; Karen N Price; Aron Goldhirsch; Barry A Gusterson; Alan S Coates Journal: J Clin Oncol Date: 2008-03-20 Impact factor: 44.544
Authors: Pamela J Goodwin; Marguerite Ennis; Mala Bahl; I George Fantus; Kathleen I Pritchard; Maureen E Trudeau; Jarley Koo; Nicky Hood Journal: Breast Cancer Res Treat Date: 2008-04-25 Impact factor: 4.872
Authors: G Berclaz; S Li; K N Price; A S Coates; M Castiglione-Gertsch; C-M Rudenstam; S B Holmberg; J Lindtner; D Erien; J Collins; R Snyder; B Thürlimann; M F Fey; C Mendiola; I Dudley Werner; E Simoncini; D Crivellari; R D Gelber; A Goldhirsch Journal: Ann Oncol Date: 2004-06 Impact factor: 32.976
Authors: Ivana Sestak; Wolfgang Distler; John F Forbes; Mitch Dowsett; Anthony Howell; Jack Cuzick Journal: J Clin Oncol Date: 2010-06-14 Impact factor: 44.544
Authors: Yujing J Heng; Jun Wang; Thomas U Ahearn; Susan B Brown; Xuehong Zhang; Christine B Ambrosone; Victor Piana de Andrade; Adam M Brufsky; Fergus J Couch; Tari A King; Francesmary Modugno; Celine M Vachon; Natalie C DuPre; Montserrat Garcia-Closas; Melissa A Troester; David J Hunter; A Heather Eliassen; Rulla M Tamimi; Susan E Hankinson; Andrew H Beck Journal: Breast Cancer Res Treat Date: 2018-11-01 Impact factor: 4.872
Authors: Mustapha Abubakar; Jenny Chang-Claude; H Raza Ali; Nilanjan Chatterjee; Penny Coulson; Frances Daley; Fiona Blows; Javier Benitez; Roger L Milne; Hermann Brenner; Christa Stegmaier; Arto Mannermaa; Anja Rudolph; Peter Sinn; Fergus J Couch; Peter Devilee; Rob A E M Tollenaar; Caroline Seynaeve; Jonine Figueroa; Jolanta Lissowska; Stephen Hewitt; Maartje J Hooning; Antoinette Hollestelle; Renée Foekens; Linetta B Koppert; Manjeet K Bolla; Qin Wang; Michael E Jones; Minouk J Schoemaker; Renske Keeman; Douglas F Easton; Anthony J Swerdlow; Mark E Sherman; Marjanka K Schmidt; Paul D Pharoah; Montserrat Garcia-Closas Journal: Int J Cancer Date: 2018-03-25 Impact factor: 7.396
Authors: Mustapha Abubakar; Changyuan Guo; Hela Koka; Bin Zhu; Joseph Deng; Nan Hu; Bin Zhou; Montserrat Garcia-Closas; Ning Lu; Xiaohong R Yang Journal: Breast Cancer Res Treat Date: 2021-06-29 Impact factor: 4.872